GlassScriptPhysician profile
William W Culbertson
NPI 1437126778
$11,229.79
in general payments reported to CMS, 2019-2025
16 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,204 · 2020: $904 · 2021: $187 · 2022: $125 · 2023: $396 · 2024: $298 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Gift: $36.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.27 |
| Gift | $36.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $8,726.72 | 2019-2023 | Tecnis Simplicity, Veritas Vision System |
| Bausch & Lomb Americas INC. | $569.87 | 2024-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Alcon Vision LLC | $454.82 | 2019-2023 | Clareon |
| Glaukos Corporation | $367.56 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Carl Zeiss Meditec USA, INC. | $282.36 | 2025 | Visumax |
| Carl Zeiss Meditec, INC. | $213.61 | 2019 | |
| Dompe US, INC. | $176.00 | 2021-2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $109.11 | 2019 | |
| Biotissue Holdings INC. | $91.31 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $27.55 | 2025 | Xdemvy |
| Santen INC. | $20.92 | 2023 | Verkazia |
| Mallinckrodt Hospital Products INC. | $19.53 | 2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $17.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $13.70 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Culbertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.